BioAdvance is a Pennsylvania-based venture fund rooted in a state-backed regional economic development mission, led by a team with deep drug-development, regulatory, and corporate venture experience. It has invested more than $50 million across nearly 100 early-stage life sciences and health technology companies—including specialized niches like NICU breast-milk management software—helping its portfolio go on to raise over $3.75 billion through follow-on funding, IPOs, and acquisitions.